Everolimus (RAD001) Significantly Extends Progression-Free Survival In Advanced Kidney Cancer Patients After Failure Of Other Targeted Therapy
An independent data monitoring committee stopped a major Phase III clinical trial of the investigational drug everolimus (RAD001) after interim results showed significantly better progression-free survival in patients with advanced kidney cancer who received everolimus compared to placebo. The committee stopped the trial of more than 400 patients conducted in 12 countries because the study met its primary endpoint.Anadys Pharmaceuticals Commences Phase I Clinical Trial Of ANA773 In Cancer Patients
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that patient dosing has commenced in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors. This first-in-human trial is a safety and tolerability study designed to identify pharmacologically active doses and preliminary antitumor activity as well as to select the dose and schedule for Phase II trials.02.28.08
AMA Applauds Bill To Research Links Between Breast Cancer And The Environment
"The American Medical Association applauds members of the U.S. Senate for their work to determine the potential links between the environment and breast cancer through the Breast Cancer and Environmental Research Act of 2007 (S. 579). Greater funding for research to better understand the relationship between breast cancer and our environment can help provide valuable information to potentially reduce the incidence of the disease.Prestigious National Award Given To UPMC Cancer Centers - Leukemia And Lymphoma Society Recognizes Commitment To Community Service
The UPMC Cancer Centers recently was awarded the National Chairman’s Citation for Excellence in Community Service from the Leukemia and Lymphoma Society. The organization was nominated by the Pittsburgh Chapter of the Society and was the only center to receive the award this year, out of over 50 nominations.
